LU93067I2 - Blinatumomab et ses dérivés pharmaceutiquement acceptables (blincyto) - Google Patents
Blinatumomab et ses dérivés pharmaceutiquement acceptables (blincyto) Download PDFInfo
- Publication number
- LU93067I2 LU93067I2 LU93067C LU93067C LU93067I2 LU 93067 I2 LU93067 I2 LU 93067I2 LU 93067 C LU93067 C LU 93067C LU 93067 C LU93067 C LU 93067C LU 93067 I2 LU93067 I2 LU 93067I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- polypeptide
- blincyto
- blinatumomab
- pharmaceutically acceptable
- binding sites
- Prior art date
Links
- 229960003008 blinatumomab Drugs 0.000 title 1
- 229940101815 blincyto Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| PCT/EP2004/013445 WO2005052004A2 (fr) | 2003-11-28 | 2004-11-26 | Compositions comprenant des polypeptides |
| EP04803302A EP1691833B1 (fr) | 2003-11-28 | 2004-11-26 | Compositions comprenant des polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU93067I2 true LU93067I2 (fr) | 2016-07-11 |
Family
ID=34626385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU93067C LU93067I2 (fr) | 2003-11-28 | 2016-05-11 | Blinatumomab et ses dérivés pharmaceutiquement acceptables (blincyto) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (fr) |
| EP (2) | EP1691833B1 (fr) |
| AT (1) | ATE459374T1 (fr) |
| AU (1) | AU2004293182B2 (fr) |
| BE (1) | BE2016C023I2 (fr) |
| CA (1) | CA2544532C (fr) |
| CY (2) | CY1110689T1 (fr) |
| DE (1) | DE602004025840D1 (fr) |
| DK (1) | DK1691833T3 (fr) |
| ES (1) | ES2341252T3 (fr) |
| FR (1) | FR16C1000I2 (fr) |
| HU (1) | HUS1600019I1 (fr) |
| LU (1) | LU93067I2 (fr) |
| NL (1) | NL300807I2 (fr) |
| PL (1) | PL1691833T3 (fr) |
| PT (1) | PT1691833E (fr) |
| SI (1) | SI1691833T1 (fr) |
| WO (1) | WO2005052004A2 (fr) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| WO2008031056A2 (fr) | 2006-09-08 | 2008-03-13 | Medimmune, Llc | Anticorps anti-cd19 humanisés, et leur utilisation dans le traitement de l'oncologie, de la transplantation et de la maladie auto-immune |
| JP5490714B2 (ja) * | 2007-11-28 | 2014-05-14 | メディミューン，エルエルシー | タンパク質製剤 |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| MA34619B1 (fr) | 2010-10-27 | 2013-10-02 | Amgen Res Munich Gmbh | Moyens et méthodes de traitement du lymphome b diffus à grandes cellules |
| CN110038135B (zh) | 2011-03-17 | 2021-03-05 | 伯明翰大学 | 重新定向的免疫治疗 |
| WO2012145714A2 (fr) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Protéines de liaison à un antigène membranaire spécifique de la prostate et compositions et procédés associés |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| CN112353943A (zh) | 2013-12-17 | 2021-02-12 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法 |
| WO2015095410A1 (fr) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Méthodes de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-cd20 |
| AP2016009586A0 (en) | 2014-05-29 | 2016-11-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| ES2819256T3 (es) | 2014-11-05 | 2021-04-15 | Genentech Inc | Métodos para producir proteínas bicatenarias en bacterias |
| EP3215526A1 (fr) | 2014-11-05 | 2017-09-13 | F. Hoffmann-La Roche AG | Procédés de production de protéines à deux chaînes dans des bactéries |
| WO2016126611A1 (fr) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Complexes d'épitope de peptide de fragment de ciblage ayant une pluralité d'épitopes de lymphocyte t |
| EP3763827A1 (fr) | 2015-05-29 | 2021-01-13 | F. Hoffmann-La Roche AG | Méthylation de promoteur de pd-l1 dans le cancer |
| HK1251493A1 (zh) | 2015-06-17 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| DK3377103T4 (en) | 2015-11-19 | 2025-05-19 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP3178848A1 (fr) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Anticorps de type ii contre cd20 pour la reduction de la formation des anticorps contre des médicaments |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| EP3400246B1 (fr) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Procédés permettant de traiter des cancers positifs à cea au moyen d'antagonistes de liaison à l'axe de pd-1 et d'anticorps bispécifiques anti-cea/anti-cd3 |
| CN110603266A (zh) | 2016-06-02 | 2019-12-20 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体 |
| EP3252078A1 (fr) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| WO2018029124A1 (fr) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Méthodes thérapeutiques et de diagnostic du cancer |
| CN110087682B (zh) | 2016-12-19 | 2023-12-15 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
| EP3559034B1 (fr) | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Thérapie de combinaison d'anticorps bispécifiques anti-cd20/anti-cd3 et agonistes 4 - 1bb (cd137) |
| TW201930353A (zh) | 2017-11-01 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 使用經靶向之ox40促效劑的組合療法 |
| CA3092002A1 (fr) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Combinaison therapeutique d'agonistes de 4-1 bb avec des anticorps anti-cd20 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| JP7383704B2 (ja) * | 2018-06-07 | 2023-11-20 | カリナン オンコロジー インコーポレイテッド | 多重特異性結合タンパク質およびその使用方法 |
| JP7475336B2 (ja) | 2018-09-21 | 2024-04-26 | ジェネンテック， インコーポレイテッド | トリプルネガティブ乳癌のための診断方法 |
| SG11202104104VA (en) | 2018-11-05 | 2021-05-28 | Genentech Inc | Methods of producing two chain proteins in prokaryotic host cells |
| EP3962948A1 (fr) | 2019-04-30 | 2022-03-09 | Amgen Research (Munich) GmbH | Moyens et méthodes de traitement du lymphome ou de la leucémie de burkitt |
| JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
| CN113874398B (zh) | 2019-05-21 | 2025-08-01 | 诺华股份有限公司 | Cd19结合分子及其用途 |
| IL293725A (en) | 2019-12-11 | 2022-08-01 | Cullinan Oncology Inc | Anti-cd19 antibodies and multispecific binding proteins |
| WO2021252917A2 (fr) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Procédés et compositions de prévention du diabète de type 1 |
| MX2022015877A (es) | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| CA3215049A1 (fr) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Agents de liaison a folr1, conjugues de ceux-ci et leurs procedes d'utilisation |
| EP4326768A1 (fr) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation |
| CN117321078A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药 |
| AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| EP4083061A1 (fr) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Protéines de fusion et leur utilisation dans le traitement de la néphropathie membraneuse |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
| CA3251878A1 (fr) | 2022-03-23 | 2023-09-28 | Genentech, Inc. | Traitement combiné associant un anticorps bispécifique anti-cd20/anti-cd3 et une chimiothérapie |
| EP4508081A1 (fr) | 2022-04-13 | 2025-02-19 | F. Hoffmann-La Roche AG | Compositions pharmaceutiques à base d'anticorps bispécifiques anti-cd20/anti-cd3 et procédés d'utilisation |
| WO2024030956A2 (fr) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Agents de liaison se liant spécifiquement à cd39 et leurs méthodes d'utilisation |
| WO2024094741A1 (fr) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Polythérapie avec un anticorps bispécifique anti-cd19/anti-cd28 |
| AU2024275646A1 (en) | 2023-05-24 | 2025-11-13 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| CN121358775A (zh) | 2023-06-21 | 2026-01-16 | 豪夫迈·罗氏有限公司 | 利用靶向FAP的淋巴毒素β受体激动剂的组合疗法 |
| TW202535954A (zh) | 2023-09-26 | 2025-09-16 | 丹麥商珍美寶股份有限公司 | Ｐｔｋ７結合劑、其共軛物及使用彼等之方法 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| WO2025149661A1 (fr) | 2024-01-10 | 2025-07-17 | Genmab A/S | Agents de liaison à slitrk6, conjugués de ceux-ci et leurs procédés d'utilisation |
| WO2025181219A1 (fr) | 2024-02-29 | 2025-09-04 | Genmab A/S | Agents de liaison bispécifiques egfr et c-met, conjugués de ceux-ci et leurs procédés d'utilisation |
| WO2025222129A2 (fr) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Cytokines modifiées et distribution ciblée de cytokines |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| DK0573551T3 (da) | 1991-02-27 | 2003-08-04 | Micromet Ag | Serinrige peptidlinkere |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| TR200003087T2 (tr) * | 1998-04-21 | 2001-02-21 | Micromet Ag | Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| NZ532896A (en) * | 2001-11-08 | 2007-08-31 | Pdl Biopharma Inc | Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab |
-
2004
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 EP EP04803302A patent/EP1691833B1/fr not_active Expired - Lifetime
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/fr not_active Ceased
- 2004-11-26 EP EP10155222A patent/EP2186527A1/fr not_active Withdrawn
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
- 2004-11-26 CA CA2544532A patent/CA2544532C/fr not_active Expired - Lifetime
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I1/el unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1691833A2 (fr) | 2006-08-23 |
| PT1691833E (pt) | 2010-06-08 |
| WO2005052004A2 (fr) | 2005-06-09 |
| CY2016010I2 (el) | 2016-08-31 |
| US20070249529A1 (en) | 2007-10-25 |
| HUS1600019I1 (hu) | 2016-06-28 |
| ES2341252T3 (es) | 2010-06-17 |
| DK1691833T3 (da) | 2010-05-03 |
| CA2544532C (fr) | 2015-06-16 |
| DE602004025840D1 (de) | 2010-04-15 |
| AU2004293182A1 (en) | 2005-06-09 |
| SI1691833T1 (sl) | 2010-06-30 |
| EP2186527A1 (fr) | 2010-05-19 |
| ATE459374T1 (de) | 2010-03-15 |
| CA2544532A1 (fr) | 2005-06-09 |
| US10000574B2 (en) | 2018-06-19 |
| CY2016010I1 (el) | 2016-08-31 |
| CY1110689T1 (el) | 2015-06-10 |
| BE2016C023I2 (fr) | 2023-12-18 |
| AU2004293182B2 (en) | 2010-02-18 |
| FR16C1000I1 (fr) | 2016-06-24 |
| FR16C1000I2 (fr) | 2017-02-03 |
| PL1691833T3 (pl) | 2010-08-31 |
| NL300807I2 (fr) | 2016-10-13 |
| WO2005052004A3 (fr) | 2006-03-09 |
| EP1691833B1 (fr) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU93067I2 (fr) | Blinatumomab et ses dérivés pharmaceutiquement acceptables (blincyto) | |
| CY1119342T1 (el) | Τριμερης πρωτεϊνη συντηξης οχ40-ανοσοσφαιρινης και μεθοδοι χρησης | |
| PT1639011E (pt) | Anticorpos (dab) de domínio único peguilados | |
| CY1118951T1 (el) | Χρηση αντισωματων υποδοχεα ιντερλευκινης-4 και συνθεσεις αυτων | |
| CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| DE60142342D1 (de) | Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen | |
| ATE469176T1 (de) | Modifizierter anti-tnf antikörper | |
| CY1111542T1 (el) | Αντισωματα εξουδετερωσης του rsv υπερυψηλης συγγενειας | |
| AR041173A1 (es) | Aniticuerpo monoclonal anti- il- 1r1 humano terapeutico | |
| DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
| EP0683234A4 (fr) | ANTICORPS DIRIGE CONTRE LE -g(b)-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION. | |
| UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
| ATE395364T1 (de) | Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung | |
| CY1115295T1 (el) | Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w | |
| DK0969873T3 (da) | Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf | |
| ATE414142T1 (de) | Anti-ccr5 antikörper | |
| AU6819600A (en) | Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections | |
| ATE122895T1 (de) | Monoklonale antikörper gegen den interleukin 2- rezeptor. | |
| WO2002087502A3 (fr) | Anticorps empechant la propagation de prions et favorisant la clairance d'une infectiosite | |
| NO20033260L (no) | Materialer omfattende sykloheksamantan | |
| WO2004035003A3 (fr) | Adjuvant therapeutique |